This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n21http://www.rxlist.com/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/wikipedia/
n13http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/kegg-drug/
n22http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00054/identifier/national-drug-code-directory/
n18http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00054
rdf:type
n3:Drug
n3:description
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
n3:dosage
n24:271B4262-363D-11E5-9242-09173F13E4C5 n24:271B4263-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8121459 # Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12939213 # FDA label
n3:group
approved
n3:halfLife
Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.
n3:indication
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
owl:sameAs
n13:DB00054 n26:DB00054
dcterms:title
Abciximab
adms:identifier
n6:Abciximab n14:DB00054 n17:0002-7140-01 n19:PA448006 n25:D02778
n3:mechanismOfAction
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.
n3:packager
n4:271B4260-363D-11E5-9242-09173F13E4C5 n4:271B425E-363D-11E5-9242-09173F13E4C5 n4:271B425F-363D-11E5-9242-09173F13E4C5 n4:271B425D-363D-11E5-9242-09173F13E4C5
n3:patent
n11:1341357
n3:synonym
C7E3 antiGPIIBIIIa 7E3 7E3 antibody
n15:hasAHFSCode
n16:92-00-00
n9:hasConcept
n10:M0227707
foaf:page
n21:reopro-drug.htm n22:abciximab.html
n3:Molecular-Formula
n8:271B4268-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B4267-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n18:B01AC13
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
143653-53-6
n3:category
n3:containedIn
n23:271B4261-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n8:271B4265-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n8:271B4266-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B4264-363D-11E5-9242-09173F13E4C5